MX2018003103A - Composiciones y procedimientos contra la malaria. - Google Patents

Composiciones y procedimientos contra la malaria.

Info

Publication number
MX2018003103A
MX2018003103A MX2018003103A MX2018003103A MX2018003103A MX 2018003103 A MX2018003103 A MX 2018003103A MX 2018003103 A MX2018003103 A MX 2018003103A MX 2018003103 A MX2018003103 A MX 2018003103A MX 2018003103 A MX2018003103 A MX 2018003103A
Authority
MX
Mexico
Prior art keywords
methods
modified
multilayer films
host
epitope
Prior art date
Application number
MX2018003103A
Other languages
English (en)
Inventor
J Powell Thomas
Gorham Boyd James
Original Assignee
Artificial Cell Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artificial Cell Tech Inc filed Critical Artificial Cell Tech Inc
Publication of MX2018003103A publication Critical patent/MX2018003103A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente memoria se describen películas multicapa que incluyen epítopos polipeptídicos modificados de Plasmodium falciparum, específicamente un epítopo T* modificado. Las películas multicapa son capaces de provocar una respuesta inmune en un huésped tras la administración al huésped. Las películas multicapa pueden incluir al menos un péptido diseñado que incluye el epítopo del polipéptido T* modificado de un protozoo de Plasmodium.
MX2018003103A 2015-09-16 2016-09-13 Composiciones y procedimientos contra la malaria. MX2018003103A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562219260P 2015-09-16 2015-09-16
PCT/US2016/051469 WO2017048689A1 (en) 2015-09-16 2016-09-13 Anti-malaria compositions and methods

Publications (1)

Publication Number Publication Date
MX2018003103A true MX2018003103A (es) 2018-06-11

Family

ID=58289798

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003103A MX2018003103A (es) 2015-09-16 2016-09-13 Composiciones y procedimientos contra la malaria.

Country Status (10)

Country Link
US (2) US9968665B2 (es)
EP (1) EP3349788A4 (es)
JP (1) JP6934862B2 (es)
CN (1) CN108025052B (es)
AU (1) AU2016322544B2 (es)
CA (1) CA2998540C (es)
HK (1) HK1254028A1 (es)
IL (1) IL257895B2 (es)
MX (1) MX2018003103A (es)
WO (1) WO2017048689A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883717B2 (en) 2012-03-30 2014-11-11 Artificial Cell Technologies, Inc. Antigenic compositions and methods
CN108025052B (zh) 2015-09-16 2022-05-10 人工细胞科技公司 抗疟疾组合物和方法
US11253482B2 (en) * 2017-07-26 2022-02-22 Albert-Ludwigs-Universitaet Freiburg Biodegradable multilayer nanocapsules for the delivery of biologically active agents in target cells
CN112789055A (zh) * 2018-10-04 2021-05-11 人工细胞科技公司 抗疟疾组合物和方法
CN113035298B (zh) * 2021-04-02 2023-06-20 南京信息工程大学 递归生成大阶数行限制覆盖阵列的药物临床试验设计方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723130A (en) 1993-05-25 1998-03-03 Hancock; Gerald E. Adjuvants for vaccines against respiratory syncytial virus
US7101575B2 (en) 1998-03-19 2006-09-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly
DE10001172A1 (de) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
EP2314630A1 (en) 2002-08-12 2011-04-27 The Council Of The Queensland Institute Of Medical Research Method of producing immunogenic lipopeptides comprising T-helper and Cytotoxic T Lymphocyte (CTL) epitopes
CA2521682A1 (en) 2003-04-10 2004-12-16 3M Innovative Properties Company Delivery of immune response modifier compounds using metal-containing particulate support materials
US7615530B2 (en) 2003-08-29 2009-11-10 Artificial Cell Technologies, Inc. Immunogenic compositions and methods of use
US7348399B2 (en) 2003-08-29 2008-03-25 Louisiana Tech University Foundation, Inc. Nanofabricated polypeptide multilayer films, coatings, and microcapsules
DE102004013637A1 (de) 2004-03-19 2005-10-13 Capsulution Nanoscience Ag Verfahren zur Herstellung von CS-Partikeln und Mikrokapseln unter Verwendung poröser Template sowie CS-Partikel und Mikrokapseln
GB0420634D0 (en) * 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
EP1850832B1 (en) 2005-02-07 2014-12-31 Lipotek PTY Ltd Adjuvanting material
DE102005044400A1 (de) 2005-09-16 2007-03-22 Capsulution Nanoscience Ag Verfahren zur Verkapselung und kontrollierten Freisetzung von schwer wasserlöslichen (hydrophoben) flüssigen und festen Wirkstoffen
CA2632703A1 (en) 2005-10-25 2008-03-13 Louisiana Tech University Research Foundation Multilayer films, coatings and microcapsules comprising polypeptides
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
US7723294B2 (en) 2007-04-02 2010-05-25 Artificial Cell Technologies, Inc. Polypeptide films and methods
EP2002847A1 (en) 2007-06-12 2008-12-17 Capsulution Nanoscience AG Drug-releasing polyelectrolyte coating, method for forming a drug-releasing polyelectrolyte coating, and implantable device
WO2009082440A2 (en) * 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use
US7846824B2 (en) 2008-03-18 2010-12-07 Applied Materials, Inc. Methods for forming a titanium nitride layer
EP2346523A4 (en) * 2008-10-01 2014-12-31 Us Health MULTICOMPONENT VACCINE AGAINST MALARIA INDUCING SUSTAINABLE IMMUNE RESPONSES AGAINST PLASMODIUM
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
WO2011022002A1 (en) * 2009-08-18 2011-02-24 The Rockefeller University Modification of recombinant adenovirus with immunogenic plasmodium circumsporozoite protein epitopes
CN103037898B (zh) 2010-07-07 2016-06-29 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
CN103402539B (zh) 2010-09-14 2016-02-24 科学与工业研究委员会 一种用于产生对抗病原体的持久免疫和保护的合成免疫原
US9433671B2 (en) * 2012-03-30 2016-09-06 Artificial Cell Technologies, Inc. Anti-malaria compositions and methods
US8883717B2 (en) 2012-03-30 2014-11-11 Artificial Cell Technologies, Inc. Antigenic compositions and methods
CA2913832C (en) * 2013-06-03 2023-07-04 Vlp Therapeutics, Llc A virus-like particle comprising a malaria antigen and use thereof as a malaria vaccine
EP3092245B1 (en) * 2014-01-09 2018-10-17 Alpha-o Peptides AG Flagellin-containing protein nanoparticles as a vaccine platform
CN108025052B (zh) 2015-09-16 2022-05-10 人工细胞科技公司 抗疟疾组合物和方法

Also Published As

Publication number Publication date
WO2017048689A1 (en) 2017-03-23
US10588954B2 (en) 2020-03-17
AU2016322544A1 (en) 2018-03-29
JP6934862B2 (ja) 2021-09-15
US20180221465A1 (en) 2018-08-09
CN108025052B (zh) 2022-05-10
AU2016322544B2 (en) 2022-08-25
US20170128558A1 (en) 2017-05-11
CA2998540C (en) 2024-04-02
IL257895B1 (en) 2023-11-01
IL257895A (en) 2018-05-31
US9968665B2 (en) 2018-05-15
IL257895B2 (en) 2024-03-01
HK1254028A1 (zh) 2019-07-12
CN108025052A (zh) 2018-05-11
JP2018529684A (ja) 2018-10-11
CA2998540A1 (en) 2017-03-23
EP3349788A1 (en) 2018-07-25
EP3349788A4 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
MX2018003103A (es) Composiciones y procedimientos contra la malaria.
IL269830A (en) Peptide-based compositions, methods of production, and uses thereof for inducing an immune response
MX2014011713A (es) Composiciones y procedimientos antipaludismo.
ZA201803978B (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
MY191581A (en) Anti-pd-1 antibodies
EP4223784A3 (en) Compositions and methods for modulating t-cell mediated immune response
MX2015008847A (es) Composiciones inmunogenicas de virus de influenza y usos de las mismas.
IL267013A (en) Tumor antigenicity processing and display
MX340796B (es) Composiciones y procedimientos antigenicos del virus respiratorio sincitial.
MX2014011712A (es) Composiciones antigenas y procedimientos.
EP3402802A4 (en) COMPOSITIONS AND METHODS FOR GENERATING AN IMMUNE RESPONSE TO ANTIGEN ASSOCIATED WITH A TUMOR
WO2015179270A3 (en) Combinatorial platform for the display of surface adjuvants and antigens
DK3269733T3 (da) Peptid afledt af gpc3, farmaceutisk sammensætning til behandling eller forebyggelse af cancer under anvendelse deraf, immunitetsinducer og fremgangsmåde til fremstilling af antigenpræsenterende celler
EP3157564A4 (en) Interferon alpha and omega antibody antagonists
MX2017008406A (es) Conjugados de aminoacidos y peptidos y sus usos.
MX2016012932A (es) Procedimientos novedosos para inducir una respuesta inmune.
EA201792512A1 (ru) Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
IN2014DN09445A (es)
EP3302531A4 (en) RECOMBINANT IMMUNE TOLERANCE ELASTINE-LIKE PEPTIDES WITHOUT IMMUNE TOLERANCE AND METHODS OF USE
EP3270958A4 (en) Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof
WO2015139020A3 (en) Vaccine compositions and methods for restoring nkg2d pathway function against cancers
NZ742663A (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
WO2015149016A3 (en) Breast and ovarian cancer vaccines
MX2021003783A (es) Composiciones y metodos antipaludicos.